Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 481

1.

Repeat length variations in ATXN1 and AR modify disease expression in Alzheimer's disease.

Gardiner SL, Harder AVE, Campman YJM, Trompet S, Gussekloo J, van Belzen MJ, Boogaard MW, Roos RAC, Jansen IE, Pijnenburg YAL, Scheltens P, van der Flier WM, Aziz NA.

Neurobiol Aging. 2018 Sep 15. pii: S0197-4580(18)30330-0. doi: 10.1016/j.neurobiolaging.2018.09.007. [Epub ahead of print]

PMID:
30314815
2.

Predictors of simulated driving performance in Huntington's disease.

Jacobs M, Hart EP, Mejia Miranda Y, Groeneveld GJ, van Gerven JMA, Roos RAC.

Parkinsonism Relat Disord. 2018 Oct 1. pii: S1353-8020(18)30433-4. doi: 10.1016/j.parkreldis.2018.10.002. [Epub ahead of print]

PMID:
30292732
3.

Altered driving performance of symptomatic Huntington's disease gene carriers in simulated road conditions.

Jacobs M, Hart EP, Miranda YM, Groeneveld GJ, van Gerven JMA, Roos RAC.

Traffic Inj Prev. 2018 Oct 1:1-7. doi: 10.1080/15389588.2018.1497796. [Epub ahead of print]

PMID:
30273496
4.

Executive impairment is associated with unawareness of neuropsychiatric symptoms in premanifest and early Huntington's disease.

Andrews SC, Craufurd D, Durr A, Leavitt BR, Roos RA, Tabrizi SJ, Stout JC.

Neuropsychology. 2018 Sep 13. doi: 10.1037/neu0000479. [Epub ahead of print]

PMID:
30211612
5.

Structural and functional changes of the visual cortex in early Huntington's disease.

Coppen EM, Grond JV, Hafkemeijer A, Barkey Wolf JJH, Roos RAC.

Hum Brain Mapp. 2018 Aug 24. doi: 10.1002/hbm.24322. [Epub ahead of print]

PMID:
30144208
6.

Repeat length variations in polyglutamine disease-associated genes affect body mass index.

Gardiner SL, de Mutsert R, Trompet S, Boogaard MW, van Dijk KW, Jukema PJW, Slagboom PE, Roos RAC, Pijl H, Rosendaal FR, Aziz NA.

Int J Obes (Lond). 2018 Aug 17. doi: 10.1038/s41366-018-0161-7. [Epub ahead of print]

PMID:
30120431
7.

Marriage as Protector for Nursing Home Admission in Huntington's Disease.

Winder JY, Achterberg WP, Roos RAC.

J Huntingtons Dis. 2018;7(3):251-257. doi: 10.3233/JHD-180305.

PMID:
30103341
8.

Apathy and atrophy of subcortical brain structures in Huntington's disease: A two-year follow-up study.

Baake V, Coppen EM, van Duijn E, Dumas EM, van den Bogaard SJA, Scahill RI, Johnson H, Leavitt B, Durr A, Tabrizi SJ, Craufurd D, Roos RAC; Track-HD investigators.

Neuroimage Clin. 2018 Mar 27;19:66-70. doi: 10.1016/j.nicl.2018.03.033. eCollection 2018.

9.

Huntington's Disease Gene Expansion Carriers Are Aware of Their Degree of Apathy.

Baake V, van Duijn E, Roos RAC.

J Neuropsychiatry Clin Neurosci. 2018 Summer;30(3):183-187. doi: 10.1176/appi.neuropsych.18020031. Epub 2018 May 30.

PMID:
29843585
10.

The visual cortex and visual cognition in Huntington's disease: An overview of current literature.

Coppen EM, van der Grond J, Hart EP, Lakke EAJF, Roos RAC.

Behav Brain Res. 2018 Oct 1;351:63-74. doi: 10.1016/j.bbr.2018.05.019. Epub 2018 May 21. Review.

PMID:
29792890
11.

Does arterial hypertension influence the onset of Huntington's disease?

Valcárcel-Ocete L, Fullaondo A, Alkorta-Aranburu G, García-Barcina M, Roos RAC, Hjermind LE, Saft C, Frontali M, Reilmann R, Rickards H; REGISTRY investigators of the European Huntington’s Disease Network (EHDN), Zubiaga AM, Aguirre A.

PLoS One. 2018 May 23;13(5):e0197975. doi: 10.1371/journal.pone.0197975. eCollection 2018.

12.

Testing a longitudinal compensation model in premanifest Huntington's disease.

Gregory S, Long JD, Klöppel S, Razi A, Scheller E, Minkova L, Johnson EB, Durr A, Roos RAC, Leavitt BR, Mills JA, Stout JC, Scahill RI, Tabrizi SJ, Rees G; Track-On investigators .

Brain. 2018 Jul 1;141(7):2156-2166. doi: 10.1093/brain/awy122.

13.

Natural biological variation of white matter microstructure is accentuated in Huntington's disease.

Gregory S, Crawford H, Seunarine K, Leavitt B, Durr A, Roos RAC, Scahill RI, Tabrizi SJ, Rees G, Langbehn D, Orth M.

Hum Brain Mapp. 2018 Apr 22. doi: 10.1002/hbm.24191. [Epub ahead of print]

14.

Dose-Dependent Lowering of Mutant Huntingtin Using Antisense Oligonucleotides in Huntington Disease Patients.

van Roon-Mom WMC, Roos RAC, de Bot ST.

Nucleic Acid Ther. 2018 Apr;28(2):59-62. doi: 10.1089/nat.2018.0720. Epub 2018 Mar 13.

PMID:
29620999
15.

Atrophy of the putamen at time of clinical motor onset in Huntington's disease: a 6-year follow-up study.

Coppen EM, van der Grond J, Roos RAC.

J Clin Mov Disord. 2018 Mar 23;5:2. doi: 10.1186/s40734-018-0069-3. eCollection 2018.

16.

Cross-sectional and longitudinal voxel-based grey matter asymmetries in Huntington's disease.

Minkova L, Gregory S, Scahill RI, Abdulkadir A, Kaller CP, Peter J, Long JD, Stout JC, Reilmann R, Roos RA, Durr A, Leavitt BR, Tabrizi SJ, Klöppel S; TRACK-HD Investigators.

Neuroimage Clin. 2017 Oct 25;17:312-324. doi: 10.1016/j.nicl.2017.10.023. eCollection 2018.

17.

Premanifest Huntington's disease: Examination of oculomotor abnormalities in clinical practice.

Winder JY, Roos RAC.

PLoS One. 2018 Mar 1;13(3):e0193866. doi: 10.1371/journal.pone.0193866. eCollection 2018.

18.

Progressive microstructural changes of the occipital cortex in Huntington's disease.

Odish OFF, Reijntjes RHAM, van den Bogaard SJA, Roos RAC, Leemans A.

Brain Imaging Behav. 2018 Feb 28. doi: 10.1007/s11682-018-9849-5. [Epub ahead of print]

PMID:
29492750
19.

Neurofilament light protein in blood predicts regional atrophy in Huntington disease.

Johnson EB, Byrne LM, Gregory S, Rodrigues FB, Blennow K, Durr A, Leavitt BR, Roos RA, Zetterberg H, Tabrizi SJ, Scahill RI, Wild EJ; TRACK-HD Study Group.

Neurology. 2018 Feb 20;90(8):e717-e723. doi: 10.1212/WNL.0000000000005005. Epub 2018 Jan 24.

20.

The contribution of gender differences in motor, behavioral and cognitive features to functional capacity, independence and quality of life in patients with Huntington's disease.

Zielonka D, Ren M, De Michele G, Roos RAC, Squitieri F, Bentivoglio AR, Marcinkowski JT, Landwehrmeyer GB.

Parkinsonism Relat Disord. 2018 Apr;49:42-47. doi: 10.1016/j.parkreldis.2018.01.006. Epub 2018 Jan 5.

PMID:
29326033
21.

Cognitive Performance and Apathy Predict Unemployment in Huntington's Disease Mutation Carriers.

Jacobs M, Hart EP, Roos RAC.

J Neuropsychiatry Clin Neurosci. 2018 Summer;30(3):188-193. doi: 10.1176/appi.neuropsych.17070144. Epub 2018 Jan 12.

PMID:
29325477
22.

Huntingtin gene repeat size variations affect risk of lifetime depression.

Gardiner SL, van Belzen MJ, Boogaard MW, van Roon-Mom WMC, Rozing MP, van Hemert AM, Smit JH, Beekman ATF, van Grootheest G, Schoevers RA, Oude Voshaar RC, Roos RAC, Comijs HC, Penninx BWJH, van der Mast RC, Aziz NA.

Transl Psychiatry. 2017 Dec 11;7(12):1277. doi: 10.1038/s41398-017-0042-1. Review.

23.

Brain Regions Showing White Matter Loss in Huntington's Disease Are Enriched for Synaptic and Metabolic Genes.

McColgan P, Gregory S, Seunarine KK, Razi A, Papoutsi M, Johnson E, Durr A, Roos RAC, Leavitt BR, Holmans P, Scahill RI, Clark CA, Rees G, Tabrizi SJ; Track-On HD Investigators.

Biol Psychiatry. 2018 Mar 1;83(5):456-465. doi: 10.1016/j.biopsych.2017.10.019. Epub 2017 Oct 26.

24.

Grey matter volume loss is associated with specific clinical motor signs in Huntington's disease.

Coppen EM, Jacobs M, van den Berg-Huysmans AA, van der Grond J, Roos RAC.

Parkinsonism Relat Disord. 2018 Jan;46:56-61. doi: 10.1016/j.parkreldis.2017.11.001. Epub 2017 Nov 2.

PMID:
29128164
25.

Recommendations for the Use of Automated Gray Matter Segmentation Tools: Evidence from Huntington's Disease.

Johnson EB, Gregory S, Johnson HJ, Durr A, Leavitt BR, Roos RA, Rees G, Tabrizi SJ, Scahill RI.

Front Neurol. 2017 Oct 10;8:519. doi: 10.3389/fneur.2017.00519. eCollection 2017.

26.

Survival End Points for Huntington Disease Trials Prior to a Motor Diagnosis.

Long JD, Mills JA, Leavitt BR, Durr A, Roos RA, Stout JC, Reilmann R, Landwehrmeyer B, Gregory S, Scahill RI, Langbehn DR, Tabrizi SJ; Track-HD and Track-On Investigators.

JAMA Neurol. 2017 Nov 1;74(11):1352-1360. doi: 10.1001/jamaneurol.2017.2107.

PMID:
28975278
27.

[Driving with Alzheimer's disease].

Jacobs M, 't Hart EP, Roos RAC.

Ned Tijdschr Geneeskd. 2017;161:D1881. Dutch.

PMID:
28914216
28.

Design optimization for clinical trials in early-stage manifest Huntington's disease.

Frost C, Mulick A, Scahill RI, Owen G, Aylward E, Leavitt BR, Durr A, Roos RAC, Borowsky B, Stout JC, Reilmann R, Langbehn DR, Tabrizi SJ, Sampaio C; TRACK-HD Investigators.

Mov Disord. 2017 Nov;32(11):1610-1619. doi: 10.1002/mds.27122. Epub 2017 Sep 14.

PMID:
28906031
29.

Cognitive decline in Huntington's disease expansion gene carriers.

Baake V, Reijntjes RHAM, Dumas EM, Thompson JC; REGISTRY Investigators of the European Huntington's Disease Network, Roos RAC.

Cortex. 2017 Oct;95:51-62. doi: 10.1016/j.cortex.2017.07.017. Epub 2017 Aug 3.

PMID:
28843844
30.

The reliability of commonly used electrophysiology measures.

Brown KE, Lohse KR, Mayer IMS, Strigaro G, Desikan M, Casula EP, Meunier S, Popa T, Lamy JC, Odish O, Leavitt BR, Durr A, Roos RAC, Tabrizi SJ, Rothwell JC, Boyd LA, Orth M.

Brain Stimul. 2017 Nov - Dec;10(6):1102-1111. doi: 10.1016/j.brs.2017.07.011. Epub 2017 Jul 31.

PMID:
28807846
31.

Body weight is a robust predictor of clinical progression in Huntington disease.

van der Burg JMM, Gardiner SL, Ludolph AC, Landwehrmeyer GB, Roos RAC, Aziz NA.

Ann Neurol. 2017 Sep;82(3):479-483. doi: 10.1002/ana.25007. Epub 2017 Aug 22.

PMID:
28779551
32.

Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis.

Byrne LM, Rodrigues FB, Blennow K, Durr A, Leavitt BR, Roos RAC, Scahill RI, Tabrizi SJ, Zetterberg H, Langbehn D, Wild EJ.

Lancet Neurol. 2017 Aug;16(8):601-609. doi: 10.1016/S1474-4422(17)30124-2. Epub 2017 Jun 7. Erratum in: Lancet Neurol. 2017 Sep;16(9):683.

33.

Large normal-range TBP and ATXN7 CAG repeat lengths are associated with increased lifetime risk of depression.

Gardiner SL, van Belzen MJ, Boogaard MW, van Roon-Mom WMC, Rozing MP, van Hemert AM, Smit JH, Beekman ATF, van Grootheest G, Schoevers RA, Oude Voshaar RC, Comijs HC, Penninx BWJH, van der Mast RC, Roos RAC, Aziz NA.

Transl Psychiatry. 2017 Jun 6;7(6):e1143. doi: 10.1038/tp.2017.116.

34.

Disease stage and plasma levels of cytokines in Huntington's disease: A 2-year follow-up study.

Bouwens JA, van Duijn E, Cobbaert CM, Roos RAC, van der Mast RC, Giltay EJ.

Mov Disord. 2017 Jul;32(7):1103-1104. doi: 10.1002/mds.26950. Epub 2017 May 29. No abstract available.

PMID:
28556406
35.

Age of onset in Huntington's disease is influenced by CAG repeat variations in other polyglutamine disease-associated genes.

Stuitje G, van Belzen MJ, Gardiner SL, van Roon-Mom WMC, Boogaard MW; REGISTRY Investigators of the European Huntington Disease Network, Tabrizi SJ, Roos RAC, Aziz NA.

Brain. 2017 Jul 1;140(7):e42. doi: 10.1093/brain/awx122. No abstract available.

PMID:
28549075
36.

Driving with a neurodegenerative disorder: an overview of the current literature.

Jacobs M, Hart EP, Roos RAC.

J Neurol. 2017 Aug;264(8):1678-1696. doi: 10.1007/s00415-017-8489-9. Epub 2017 Apr 19. Review.

37.

Topological length of white matter connections predicts their rate of atrophy in premanifest Huntington's disease.

McColgan P, Seunarine KK, Gregory S, Razi A, Papoutsi M, Long JD, Mills JA, Johnson E, Durr A, Roos RAC, Leavitt BR, Stout JC, Scahill RI, Clark CA, Rees G, Tabrizi SJ, Investigators TTH.

JCI Insight. 2017 Apr 20;2(8). pii: 92641. doi: 10.1172/jci.insight.92641. [Epub ahead of print]

38.

Operationalizing compensation over time in neurodegenerative disease.

Gregory S, Long JD, Klöppel S, Razi A, Scheller E, Minkova L, Papoutsi M, Mills JA, Durr A, Leavitt BR, Roos RAC, Stout JC, Scahill RI, Langbehn DR, Tabrizi SJ, Rees G.

Brain. 2017 Apr 1;140(4):1158-1165. doi: 10.1093/brain/awx022. No abstract available.

39.

The Effect of Music Therapy in Patients with Huntington's Disease: A Randomized Controlled Trial.

van Bruggen-Rufi MC, Vink AC, Wolterbeek R, Achterberg WP, Roos RA.

J Huntingtons Dis. 2017;6(1):63-72. doi: 10.3233/JHD-160229.

PMID:
28304313
40.

White matter predicts functional connectivity in premanifest Huntington's disease.

McColgan P, Gregory S, Razi A, Seunarine KK, Gargouri F, Durr A, Roos RA, Leavitt BR, Scahill RI, Clark CA, Tabrizi SJ, Rees G; Track On‐HD Investigators, Coleman A, Decolongon J, Fan M, Petkau T, Jauffret C, Justo D, Lehericy S, Nigaud K, Valabrègue R, Choonderbeek A, Hart EP, Hensman Moss DJ, Crawford H, Johnson E, Papoutsi M, Berna C, Reilmann R, Weber N, Stout J, Labuschagne I, Landwehrmeyer B, Orth M, Johnson H.

Ann Clin Transl Neurol. 2017 Jan 16;4(2):106-118. doi: 10.1002/acn3.384. eCollection 2017 Feb.

41.

Current Pharmacological Approaches to Reduce Chorea in Huntington's Disease.

Coppen EM, Roos RA.

Drugs. 2017 Jan;77(1):29-46. doi: 10.1007/s40265-016-0670-4. Review.

42.

Plasma Cytokine Levels in Relation to Neuropsychiatric Symptoms and Cognitive Dysfunction in Huntington's disease.

Bouwens JA, van Duijn E, Cobbaert CM, Roos RA, van der Mast RC, Giltay EJ.

J Huntingtons Dis. 2016 Dec 15;5(4):369-377.

PMID:
27983562
43.

Early grey matter changes in structural covariance networks in Huntington's disease.

Coppen EM, van der Grond J, Hafkemeijer A, Rombouts SA, Roos RA.

Neuroimage Clin. 2016 Oct 12;12:806-814. eCollection 2016.

44.

Reply: Late onset Huntington's disease with 29 CAG repeat expansion.

Oosterloo M, Van Belzen MJ, Bijlsma EK, Roos RA.

J Neurol Sci. 2016 Sep 15;368:343. doi: 10.1016/j.jns.2016.07.021. Epub 2016 Jul 22. No abstract available.

PMID:
27538661
45.

Natural variation in sensory-motor white matter organization influences manifestations of Huntington's disease.

Orth M, Gregory S, Scahill RI, Mayer IS, Minkova L, Klöppel S, Seunarine KK, Boyd L, Borowsky B, Reilmann R, Bernhard Landwehrmeyer G, Leavitt BR, Roos RA, Durr A, Rees G, Rothwell JC, Langbehn D, Tabrizi SJ; TRACK-On Investigators.

Hum Brain Mapp. 2016 Dec;37(12):4615-4628. doi: 10.1002/hbm.23332. Epub 2016 Aug 1.

PMID:
27477323
46.

Progression of motor subtypes in Huntington's disease: a 6-year follow-up study.

Jacobs M, Hart EP, van Zwet EW, Bentivoglio AR, Burgunder JM, Craufurd D, Reilmann R, Saft C, Roos RA; REGISTRY investigators of the European Huntington’s Disease Network.

J Neurol. 2016 Oct;263(10):2080-5. doi: 10.1007/s00415-016-8233-x. Epub 2016 Jul 19.

47.

Suicidality in Huntington's Disease: A Qualitative Study on Coping Styles and Support Strategies.

Hubers AA, Hamming A, Giltay EJ, von Faber M, Roos RA, van der Mast RC, van Duijn E.

J Huntingtons Dis. 2016 May 31;5(2):185-98. doi: 10.3233/JHD-160188.

PMID:
27258585
48.

Participants at the Leiden Site of the REGISTRY Study: A Demographic Approach.

Baake V, Hart EP, Bos R, Roos RA.

J Huntingtons Dis. 2016;5(1):83-90. doi: 10.3233/JHD-150157.

PMID:
27003663
49.

Medication Use in Early-HD Participants in Track-HD: an Investigation of its Effects on Clinical Performance.

Keogh R, Frost C, Owen G, Daniel RM, Langbehn DR, Leavitt B, Durr A, Roos RA, Landwehrmeyer GB, Reilmann R, Borowsky B, Stout J, Craufurd D, Tabrizi SJ.

PLoS Curr. 2016 Jan 11;8. pii: ecurrents.hd.8060298fac1801b01ccea6acc00f97cb. doi: 10.1371/currents.hd.8060298fac1801b01ccea6acc00f97cb.

50.

Longitudinal Diffusion Tensor Imaging Shows Progressive Changes in White Matter in Huntington's Disease.

Gregory S, Cole JH, Farmer RE, Rees EM, Roos RA, Sprengelmeyer R, Durr A, Landwehrmeyer B, Zhang H, Scahill RI, Tabrizi SJ, Frost C, Hobbs NZ.

J Huntingtons Dis. 2015;4(4):333-46. doi: 10.3233/JHD-150173.

Supplemental Content

Support Center